Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.

@article{Bellone2016SolitomabAE,
  title={Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.},
  author={S. Bellone and J. Black and D. English and Carlton L. Schwab and S. Lopez and E. Cocco and E. Bonazzoli and Federica Predolini and F. Ferrari and E. Ratner and D. Silasi and M. Azodi and P. Schwartz and A. Santin},
  journal={American journal of obstetrics and gynecology},
  year={2016},
  volume={214 1},
  pages={
          99.e1-8
        }
}
BACKGROUND Uterine serous carcinoma is an aggressive form of endometrial cancer that carries an extremely poor prognosis. Solitomab is a novel bispecific single-chain antibody construct that targets epithelial cell adhesion molecule on tumor cells and also contains a CD3 binding region. We evaluated the expression levels of epithelial cell adhesion molecule and the in vitro activity of solitomab against primary uterine serous carcinoma cell lines in vitro and ex-vivo in the ascites of patients… Expand
Immunotherapy in endometrial cancer - an evolving therapeutic paradigm
Immunotherapy in endometrial cancer: new scenarios on the horizon

References

SHOWING 1-10 OF 26 REFERENCES
EpCAM: A New Therapeutic Target for an Old Cancer Antigen
The biology of the 17–1A antigen (Ep-CAM)
...
1
2
3
...